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NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING
IN CONTEXT OF SURVIVAL AND COMPLICATIONS
Aulakh TS, Robinson EV, Richardson JB
RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK
OBJECTIVES: Metal on metal arthroplasty is gaining acceptance
around the globe. The procedure preserves bone stock and pro-
vides increased range of motion. So far good short-term results
have been reported. We present the results of a nine year fol-
low up of 4771 patients with Birmingham hip resurfacing.
METHODS: In total, 4771 patients were included in this study
and their details were entered into the Oswestry Outcome Centre
database. These patients were operated by 137 surgeons from all
around the world. All the patients were followed up annually and
asked to inform the outcome centre in case they had a revision.
Kaplan-Meier method was used to analyze the survival of this
implant for different end points. Survival times were compared
using log rank test (Mantel method). RESULTS: Out of 4771
patients there were 117 failures. Overall survival rate of the
implant at nine years was 93.5 %. Two complications i.e. frac-
ture neck of femur and implant loosening occurred in 38 and 32
patients respectively. Survival rate with fracture as the end point
was 97.5% and 98.8% with loosening as the end point. There
was a signiﬁcant difference between survival rates of patients
operated by pioneering surgeons (96.1%) as compared to others
(65.9%) (p < 0.001). Similar difference was observed between
survival rates of each group with fracture (99.0% and 69.6%)
(p < 0.001) and loosening (99.8% and 96.4%) (p < 0.001)
respectively. CONCLUSION: Our results show a signiﬁcant dif-
ference in incidence of fracture neck of femur following hip
resurfacing in non pioneering surgeons. This may be indicative of
a learning curve in the nonpioneering surgeons.
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THE COST-EFFECTIVENESS OFTITANIUM CAGEVERSUS
FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR
FUSION:A RANDOMISED CONTROLLEDTRIAL
Sach TH1, Steele NA2, Hegarty J2, Soegaard R3, Freeman BJ2
1University of Nottingham, Nottingham, UK, 2Nottingham University
Hospitals NHS Trust, Nottingham, UK, 3University of Aarhus, Aarhus,
Denmark
OBJECTIVES: To determine the cost-effectiveness of titanium
cage (TC) (new intervention) versus femoral ring allograft (FRA)
(standard intervention) in circumferential lumbar spinal fusion.
A secondary aim was to assess whether using different methods
of dealing with missing utility data changed the study conclusion
reached. METHODS: A cost utility analysis was undertaken
alongside a prospective controlled trial of 78 participants ran-
domised to TC (n = 41) or FRA (n = 37) surgery between 1998
and 2002 from a secondary care NHS perspective. NHS
resources relating to the surgery and any revision surgery needed
during the 2 year trial period were record in clinical records and
valued using local unit costs where available or published
national unit costs. The Short Form-6D (based on 11 questions
from the Short Form-36 patient questionnaire) was administered
preoperatively and at 6, 12, and 24 months in order to elicit
patient utility and derive Quality-Adjusted Life Years (QALYs)
for the trial period. Bootstrapped mean differences in costs and
beneﬁts were generated. Missing utility data was imputed using
linear interpolation in the base case but complete case analysis,
available case analysis, and multiple imputation were also under-
taken. RESULTS: A signiﬁcant mean cost saving of1942 (95%
conﬁdence interval 849 to 3145) was associated with FRA
(UK 2005/6). Mean QALYs per patient over the 24 month trial
period were 0.0522 (SD 0.0326) in the TC group and 0.1914 (SD
0.0398) in the FRA group, producing a signiﬁcant difference of
-0.1392 (95% conﬁdence interval –0.2349 to –0.0436). Using
multiple imputation resulted in a mean difference of –0.1367
compared to –0.0675 using available case analysis and –0.0518
using complete case analysis. CONCLUSION: From a secondary
care NHS perspective, TC is not cost-effective in circumferential
lumbar fusion compared to the FRA. The method of dealing with
missing utility data had no impact on this conclusion.
PODIUM SESSION III: DIABETES
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IMPACT OF ROSIGLITAZONETHERAPY ONTHE LIPID
PROFILE AND LIPID-LOWERINGTREATMENT INTYPE 2
DIABETES PATIENTS
Suh DC1, Huang J1, Nocea G2,Yin D3, Krishnarajah G3
1Rutgers University, Piscataway, NJ, USA, 2MSD Spain, Madrid, Spain,
3Merck & Co., Inc,Whitehouse Station, NJ, USA
OBJECTIVES: To assess the impact of adding rosiglitazone
(ROSI) treatment to metformin or sulphonylurea on the lipid
proﬁles and daily medication costs (Med-costs) in type 2 diabetes
patients (Type2-DM). METHODS: Type2-DM patients were
identiﬁed based on the diagnosis or use of glucose lowering drugs
during January 1,1999-June 30, 2004 using UK General-Practice-
Research-Database (GPRD). ROSI patients were matched 1:1 to
control patients using propensity scores and these patients were
followed from the ﬁrst date of the add-on therapy until the end of
the 18-month follow-up period. A1C, cholesterol, and Med-costs
of lipid and glucose lowering medications were compared before
and after add-on therapy between the cohorts. Changes in the
study variables were tested using t-test and analysis of covariance,
and the mean and 95% conﬁdence intervals for Med-costs were
calculated by the bootstrap method. All Med-costs were based on
2007 UK pounds. RESULTS: The study matched 2669 pairs of
patients, resulting in mean age of 59 and 44% female. None of the
variables used for the propensity scores were signiﬁcant after
matching. After add-on therapy, a signiﬁcant increase of the total
cholesterol by 3.1% was found in the ROSI group, while a
signiﬁcant decrease of -6.4% was found in the control group
(p < 0.001). A1C was reduced by 0.77% in ROSI and 0.98% in
control patients. A total of 734 patients added lipid lowering drug
after index date in the ROSI group compared to only 600 in
control group. The estimated increase of lipid lowering daily drug
cost in the ROSI group after add-on therapy was greater than that
of the control group, averaging 0.14 vs. 0.11 respectively.
CONCLUSION: After addition of rosiglitazone to metformin or
sulphonylurea, patients achieved reductions in A1C, but also
signiﬁcant increases in total cholesterol, which resulted in
increased use of lipid lowering drugs with associated costs.
DB2
COMPARING BRITISH AND GERMAN DIABETES GUIDANCE
WITH RESPECTTO LONGTERM OUTCOMES AND
ASSOCIATED COSTS: RESULTS FROMTHE EAGLE DIABETES
SIMULATION MODEL
Mueller E1, Huppertz E2, Stridde E3
1Analytica International, Loerrach, Germany, 2Consultant HE&RO,
Niedererbach, Germany, 3Pﬁzer Pharma GmbH, Karlsruhe, Germany
OBJECTIVES: Based on diabetes guidance from NICE (UK) and
the German Diabetes Association (DDG) on treatment targets
virtual type 2 diabetes patient cohorts were simulated over 10
years using the EAGLE model. Development of long-term com-
plications and associated costs of both guidance were compared
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from a German perspective. METHODS: The Economic Assess-
ment of Glycemic Control and Longterm Effects (EAGLE) model
provides micro-simulations of virtual patients in 1-year cycles.
Outcomes presented as cumulative incidence include micro- and
macrovascular complications and death. Subsequent cost calcu-
lations are constructed from the results. Main factors driving the
development of complications are HbA1c, blood pressure, lipids,
age, diabetes duration and treatment. Baseline characteristics of
each cohort (1000 patients) were: age 64  11 years, diabetes
duration 10  8 years, 49% male, hypertension prevalence 80%,
mean HbA1c 7.7  1.8%, HDL 1.11 mmol/l, LDL 3.84 mmol/l.
For comparison a) HbA1c treatment targets of 7.0% (UK) and
6.4% (DDG) were simulated. For comparison b) additionally
control of LDL, HDL and blood pressure was simulated accord-
ing the two guidelines. All cost data were provided by CoDiM
study. Long-term outcomes, risk reductions and costs were com-
pared from the German perspective. RESULTS: More strict gly-
cemic, blood pressure and lipid control according to the DDG
guidance reduces longterm complications substantially compared
to the UK guidance: incidences for proliferative retinopathy,
ESRD and MI were lower by 14%, 23% and 11%. Accordingly,
associated cost savings were 26T€, 366T€ and 148T€ following
the DDG guidance. Savings in the treatment of complications
amount to 965T€. Inclusion of diabetes treatment cost results in
overall savings of 186T€. CONCLUSION: Guidance for diabetes
treatment vary between EU-countries. The simulation analyses
from the German perspective demonstrated that preferably a
more stingent guidance should be applied with respect to long-
term outcomes and costs.
DB3
CLINICAL AND PATIENT REPORTED OUTCOMES OVERTHE
FIRST 6 MONTHS OF INSULINTHERAPY IN PATIENTS WITH
TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM:
DATA FROMTHE INSTIGATE STUDY
Timlin L1,Tynan A1, Simpson A1, Liebl A2, Jones S3
1Eli Lilly and Company Limited, Surrey, UK, 2Fachklinik Bad Heilbrunn,
Bad Heilbrunn, Germany, 3The James Cook University Hospital,
Middlesborough, UK
OBJECTIVES: An objective of the INSTIGATE study is to
describe clinical and patient reported outcomes after 6 months of
insulin therapy in patients with type 2 diabetes. This abstract
presents data from patients enrolled in Germany and UK.
METHODS: INSTIGATE is an ongoing prospective European
observational study investigating patients with type 2 diabetes
who initiated insulin during usual care. Data on outcomes were
collected at baseline and at 3 and 6 months following insulin
initiation. RESULTS: A total of 509 patients were enrolled in
Germany and UK. Six-month follow-up data was collected
from 457 patients. Clinical outcomes, mean (SD), changed from
baseline to six months post insulin initiation as follows: FBG
improved from 11.5 (4.7) mmol/l to 6.9 (1.8) mmol/l in Germany
and from 13.3 (4.9) mmol/l to 10.2 (4.3) mmol/l in UK. HbA1c
improved from 9.2 (2.0)% to 6.9 (1.0)% in Germany and from
10.2 (1.7)% to 8.4 (1.4)% in UK. BMI increased from 30.5
(6.0) kg/m2 to 31.0 (5.9) kg/m2 in Germany and from 31.9
(6.6) kg/m2 to 32.5 (5.6) kg/m2 in UK. Improvements were seen
in health status using the EQ-5D; in Germany the median visual
analogue scale score increased from 70 to 79 and in UK from 65
to 70. The number of patients self-reporting hypoglycaemic
episodes increased as follows for German and UK patients
respectively; in the 3 months before insulin initiation 9 (3.5%)
and 13 (5.1%) patients experienced a total of 31 episodes in each
country, and in the 3 months before the six-month follow-up
visit 26 (11.2%) and 57 (25.4%) patients experienced a total of
153 and 221 episodes. CONCLUSION: Differences in baseline
characteristics and initial insulin regimes prescribed in UK
and German patients were observed. Glycaemic control and
health-related quality-of-life improved in the 6 months following
insulin initiation. However BMI and rates of hypoglycaemia
increased.
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TREATMENT ADHERENCE AND BARRIERSTO ADHERENCE
ARE ASSOCIATED WITH GLYCEMIC CONTROL AND
EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH
TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL
ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
Alvarez-Guisasola F1, Martin Castillo F2, Krishnarajah G3, Lyu R4,
Mavros P4,Yin D4
1Centro de Salud La Calzada II, Gijón, Spain, 2Hospital General de
Móstoles, Madrid, Spain, 3Merck & Co,Whitehouse Station, NJ, USA,
4Merck & Co., Inc,Whitehouse Station, NJ, USA
OBJECTIVES: To assess the association of adherence to treat-
ment with gylcemic control and patient experience of hypo-
glycemic symptoms in adult T2DM patients, who added a
sulfonyurea(SU) or glitazone(PPAR) to metformin(MF) mono-
therapy. METHODS: A retrospective clinical chart review and
patient survey during physician visit (June’06–Feb’07) was
conducted in 7 countries (Finland, France, Germany, Norway,
Poland, Spain, UK). Patients recruited (aged 30 years) added SU
or PPARf¥ to MF. A1C refers to the most recent measurement
within a year prior to enrollment. Glycemic control was deﬁned
according to the IDF (2005) recommendations as A1C < 6.5%.
Questionnaires were used to ascertain experience of hypogly-
cemia and adherence to treatment. A questionnaire published
by Grant et al. (2003), was modiﬁed and used to measure
patient reported adherence to OHA. RESULTS: A total of
1709 patients were included in this analysis. Average age 63
(SD = 11) years, 45% female, and 50% were diagnosed with
diabetes > than 7 years. The mean A1C was 7.1% (SD = 1.1),
while 28% (477 patients) had adequate glycemic control. IN
all, 652 (38%) reported hypoglycemic symptoms. Sixty-nine
percent reported that they always take their diabetes medica-
tions exactly as prescribed. Reported barriers to adherence
were: 1) being unable to follow plan for diabetes (45.5%); 2)
bothered by adverse effects (40.9%); 3) being unsure about
physician instructions (32.9%); and 4) having difﬁculty ﬁlling
prescriptions (23.6%). Experience of hypoglycemic symptoms
was associated with higher odds of reporting: a barrier due to
adverse effects (Odds Ratio (OR): 2.54; 95% CI: 2.1–3.1);
unsure of doctor’s instructions (OR: 1.34; 95% CI: 1.1–1.7);
unable to follow plan for diabetes (OR: 1.3; 95% CI: 1.1–
1.6); having difﬁculty ﬁlling prescriptions (OR: 1.4; 95% CI:
1.1–1.7). Patients always taking medications exactly as pre-
scribed had higher odds of having adequate glycemic control
(OR: 1.3; 95% CI: 1.05–1.68). CONCLUSION: Adequate
glycemic control was found in 28% of patients and 38% of all
patients experienced hypoglycemic symptoms. Experience of
hypoglycemic symptoms was associated with barriers to adher-
ence, while adherence to therapy improved the odds of having
adequate glycemic control.
A232 Abstracts
